For years, the gap between what Americans pay for prescription drugs and what patients in other developed nations pay has been a point of contention in public health. In the United States, drug prices are often estimated to be three times higher than in comparable countries. For the Medicaid program, which serves millions of the country’s most vulnerable populations, these costs represent a growing budgetary pressure that both state and federal governments are desperate to curb.
Enter the GENEROUS model—an acronym for GENErating cost Reductions fOr U.S. Medicaid. Launched by the CMS Innovation Center in January 2026, this initiative attempts to bridge the pricing gap by implementing a “most-favored-nation” (MFN) framework. The premise is straightforward: the U.S. Government should not pay more for a drug than other comparable nations do. If successful, the White House estimates the model could save $64.3 billion over a decade, averaging roughly $6.43 billion annually, or about 14% of annual Medicaid prescription drug spending.
As a physician and medical writer, I have seen how the complexity of drug pricing often obscures the actual cost of care. The GENEROUS model is an ambitious attempt to bring transparency and international parity to the table, but the path from a policy goal to actual savings is fraught with variables. From proprietary rebate data to the voluntary nature of participation, the real-world impact of the model remains an open question.
How the MFN Pricing Mechanism Works
The core of the GENEROUS model is the negotiation of supplemental drug rebates based on international benchmarks. CMS does not simply pick the cheapest price available globally; instead, it looks at the net prices in eight specific countries: the United Kingdom, France, Germany, Italy, Canada, Japan, Denmark and Switzerland.
To determine the “MFN price,” CMS identifies the second-lowest reported net price among these nations, adjusting for gross domestic product (GDP) per capita using a purchasing power parity method. CMS then calculates a supplemental rebate for brand-name drugs (single-source or innovator multiple-source drugs) to ensure the net price paid by Medicaid is equivalent to that international benchmark.
Beyond pricing, the model seeks to standardize how drugs are accessed. CMS and participating manufacturers are negotiating uniform coverage criteria, which include utilization controls like step therapy or prior authorization. While this could reduce the administrative burden for states that currently negotiate their own individual agreements, there is a risk that these standardized criteria could be more restrictive than existing state rules, potentially impacting patient access.
The Logistics of Participation and Deadlines
The GENEROUS model is not a mandate; it is a voluntary experiment. For manufacturers, participation is closely tied to broader trade incentives. Seventeen pharmaceutical companies, including giants like Pfizer and AstraZeneca, have already signed MFN agreements in exchange for a three-year reprieve from certain tariffs. However, the specific details of these confidential agreements remain shielded from public view.
States must also opt-in to receive the MFN pricing. Because states can select which specific drugs they want to include in the model, the total savings will depend heavily on how many states participate and which medications they prioritize.
| Milestone | Deadline/Date |
|---|---|
| Model Launch | January 2026 |
| Manufacturer Application Deadline | June 11, 2026 |
| State Application Deadline | July 31, 2026 |
| State Participation Agreement Execution | August 31, 2026 |
| Model Conclusion | December 31, 2030 |
Why Actual Savings May Differ from Estimates
While the $64.3 billion figure sounds definitive, the math of Medicaid drug spending is notoriously opaque. The primary hurdle is that Medicaid already employs a robust rebate system. Between FY 2019 and FY 2024, existing rebates reduced gross Medicaid prescription spending by an average of 53%. For brand-name drugs, that reduction can be even steeper.
The potential for savings depends largely on the type of drug. Newer medications with little to no competition—such as Biktarvy, an HIV treatment—often have smaller existing rebates. For these drugs, the GENEROUS model could lead to significant savings for states. Conversely, older drugs with more competitors, such as the anticoagulant Eliquis, may already have rebates so high that the Medicaid program is paying nearly nothing, leaving little room for further MFN-driven reductions.
the impact varies wildly by state. Recent data shows that while some states (like Delaware or Wyoming) see rebates reducing gross spending by over 90%, others (like Kentucky or Oregon) see reductions of less than 40%. States with lower existing rebate efficiency stand to gain the most from the GENEROUS model.
Concentrated Spending and Clinical Access
The success of the model may ultimately hinge on a particularly small number of medications. Analysis of Medicaid State Drug Utilization Data reveals a high concentration of spending: the top five drugs—including Humira, Stelara, Dupixent, and Ozempic—account for 10% of all Medicaid drug spending. The top 50 drugs account for more than one-third of the total spend.
If the GENEROUS model successfully captures these high-spend, high-utilization drugs, the savings could be transformative. However, if manufacturers are able to secure exemptions for their most profitable blockbusters, the model’s impact may be marginal. The Senate Finance Committee has already begun sending letters to manufacturers pushing for more clarity on which specific drugs will be included in the model.
It is also important to note that while these negotiations target the program’s expenditures, they are not designed to change the out-of-pocket costs for enrollees, which remain limited to nominal amounts under federal law.
As the 2026 deadlines approach, the focus shifts to state administrators. Many states are currently facing severe budget pressures and federal cuts, making them more likely to adopt any viable cost-containment strategy. The next critical checkpoint will be August 31, 2026, the deadline for states to execute their participation agreements with CMS. The volume of state sign-ups by that date will be the first real indicator of whether the GENEROUS model is viewed as a practical tool for savings or an administrative hurdle.
We want to hear from you. Do you believe international pricing benchmarks are the right way to lower U.S. Drug costs? Share your thoughts in the comments below or share this story with your network.
Worth a look
